BSC
NBIX icon

BOLTON SECURITIES CORPORATION’s Neurocrine Biosciences NBIX Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.59K Buy
+50
New +$6.63K ﹤0.01% 1708
2025
Q3 		$7.02K Buy
+50
New +$6.78K ﹤0.01% 1630
2025
Q1 		$5.53K Buy
+50
New +$6.33K ﹤0.01% 1560

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's NBIX Position: Q1 2026 in Review

BOLTON SECURITIES CORPORATION opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 50 shares worth $6.59K. The stake represents ﹤0.01% of the portfolio and ranks #1708 among its holdings. This is a return to the name: BOLTON SECURITIES CORPORATION previously reported a position in NBIX as recently as Q3 2025.

BOLTON SECURITIES CORPORATION first reported a position in NBIX in Q1 2025 and has held it in 3 quarters since. The position peaked at $7.02K in Q3 2025. 703 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • BOLTON SECURITIES CORPORATION held 50 shares of Neurocrine Biosciences worth $6.59K as of Q1 2026.
  • Neurocrine Biosciences was a new BOLTON SECURITIES CORPORATION position in Q1 2026.
  • Neurocrine Biosciences made up ﹤0.01% of BOLTON SECURITIES CORPORATION's portfolio in Q1 2026, its #1708 holding.
  • BOLTON SECURITIES CORPORATION first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 3 quarters since.
  • BOLTON SECURITIES CORPORATION's Neurocrine Biosciences position peaked at $7.02K in Q3 2025.
  • 703 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q1 2026, filed 12 Nov 2026.